Endocrine therapy in the management of low-grade serous ovarian/peritoneal carcinoma: Mounting evidence for therelative efficacy of tamoxifen and aromatase inhibitors

Gynecol Oncol. 2020 Dec;159(3):601-603. doi: 10.1016/j.ygyno.2020.09.049. Epub 2020 Oct 2.
No abstract available

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Aromatase Inhibitors / therapeutic use*
  • Breast / pathology
  • Cystadenocarcinoma, Serous / diagnosis
  • Cystadenocarcinoma, Serous / drug therapy*
  • Cystadenocarcinoma, Serous / mortality
  • Cystadenocarcinoma, Serous / secondary
  • Female
  • Humans
  • Neoplasm Grading
  • Ovarian Neoplasms / diagnosis
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / mortality
  • Ovarian Neoplasms / pathology
  • Peritoneal Neoplasms / diagnosis
  • Peritoneal Neoplasms / drug therapy*
  • Peritoneal Neoplasms / mortality
  • Peritoneal Neoplasms / secondary
  • Peritoneum / pathology
  • Progression-Free Survival
  • Receptors, Estrogen / metabolism
  • Receptors, Progesterone / metabolism
  • Tamoxifen / therapeutic use

Substances

  • Antineoplastic Agents, Hormonal
  • Aromatase Inhibitors
  • Receptors, Estrogen
  • Receptors, Progesterone
  • Tamoxifen